Genzyme's Clolar fails to gain support of FDA panel

09/2/2009 | Reuters

Genzyme did not get support from an FDA advisory panel to market pediatric leukemia drug Clolar to adults with acute myeloid leukemia. In a 9-3 vote, the panel advised the company to conduct a randomized trial of Clolar to provide "an evidence-based justification" that the product is more effective than other treatments.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Antibiotics and Innovation Project
The Pew Charitable Trusts
Washington, DC
Healthcare Compliance Manager
Ernst & Young
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Health Plan CEO - Oregon
Trillium Community Health Plan
Eugene, OR
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC